As of close of business last night, Revance Therapeutics Inc’s stock clocked out at $3.97, down -3.87% from its previous closing price of $4.13. On the day, 2121974 shares were traded.
Ratios:
To gain a deeper understanding of RVNC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 3.80.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $16 previously.
On January 09, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $30 to $8.
Exane BNP Paribas Upgraded its Underperform to Neutral on August 16, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 18 ’24 when Schilke Tobin sold 9,361 shares for $5.04 per share. The transaction valued at 47,204 led to the insider holds 192,666 shares of the business.
Sjuts Dustin S sold 9,211 shares of RVNC for $46,446 on Mar 18 ’24. The President now owns 167,550 shares after completing the transaction at $5.04 per share. On Mar 18 ’24, another insider, Moxie Dwight, who serves as the CLO & GC of the company, sold 8,125 shares for $5.04 each. As a result, the insider received 40,971 and left with 137,815 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.77.
Stock Price History:
Over the past 52 weeks, RVNC has reached a high of $37.98, while it has fallen to a 52-week low of $4.10.
Shares Statistics:
A total of 104.22M shares are outstanding, with a floating share count of 95.22M. Insiders hold about 8.64% of the company’s shares, while institutions hold 75.45% stake in the company.
Earnings Estimates
As of right now, Revance Therapeutics, Inc. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $25.26, with high estimates of $22.28 and low estimates of $0.00.
EPS for the following year is $ETF, with Stocks analysts recommending between $ETF and $Stocks.
